140 related articles for article (PubMed ID: 37078537)
21. Novel insights into the systemic treatment of lung cancer malignant pleural effusion.
Tissot C; Gay P; Brun C; Froudarakis ME
Clin Respir J; 2019 Mar; 13(3):131-138. PubMed ID: 30737898
[TBL] [Abstract][Full Text] [Related]
22. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
[TBL] [Abstract][Full Text] [Related]
23. Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient.
Wang Y; Liu Z; Yin H; Hu J; Zhong S; Chen W; Zhao J
Gene; 2018 Feb; 644():87-92. PubMed ID: 29097164
[TBL] [Abstract][Full Text] [Related]
24. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
[TBL] [Abstract][Full Text] [Related]
26. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.
Schwalk AJ; Ost DE; Saltijeral SN; De La Garza H; Casal RF; Jimenez CA; Eapen GA; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee J; Elamin Y; Zhang J; Roth JA; Swisher S; Heymach JV; Grosu HB
Chest; 2021 Mar; 159(3):1256-1264. PubMed ID: 33217413
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions.
Hung MS; Lin CK; Leu SW; Wu MY; Tsai YH; Yang CT
Chang Gung Med J; 2006; 29(4):373-9. PubMed ID: 17051834
[TBL] [Abstract][Full Text] [Related]
29. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
[TBL] [Abstract][Full Text] [Related]
30. Sea-urchin-like Au nanocluster with surface-enhanced raman scattering in detecting epidermal growth factor receptor (EGFR) mutation status of malignant pleural effusion.
Wang L; Guo T; Lu Q; Yan X; Zhong D; Zhang Z; Ni Y; Han Y; Cui D; Li X; Huang L
ACS Appl Mater Interfaces; 2015 Jan; 7(1):359-69. PubMed ID: 25495142
[TBL] [Abstract][Full Text] [Related]
31. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
32. Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions.
Villatoro S; Mayo-de-Las-Casas C; Jordana-Ariza N; Viteri-Ramírez S; Garzón-Ibañez M; Moya-Horno I; García-Peláez B; González-Cao M; Malapelle U; Balada-Bel A; Martínez-Bueno A; Campos R; Reguart N; Majem M; Blanco R; Blasco A; Catalán MJ; González X; Troncone G; Karachaliou N; Rosell R; Molina-Vila MA
Mol Oncol; 2019 Dec; 13(12):2633-2645. PubMed ID: 31529604
[TBL] [Abstract][Full Text] [Related]
33. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients.
Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
Cancer Sci; 2006 Jul; 97(7):642-8. PubMed ID: 16827805
[TBL] [Abstract][Full Text] [Related]
34. Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing.
Lin J; Gu Y; Du R; Deng M; Lu Y; Ding Y
Int J Clin Exp Pathol; 2014; 7(12):8813-22. PubMed ID: 25674250
[TBL] [Abstract][Full Text] [Related]
35. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.
Rizzo S; Petrella F; Buscarino V; De Maria F; Raimondi S; Barberis M; Fumagalli C; Spitaleri G; Rampinelli C; De Marinis F; Spaggiari L; Bellomi M
Eur Radiol; 2016 Jan; 26(1):32-42. PubMed ID: 25956936
[TBL] [Abstract][Full Text] [Related]
36. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
[TBL] [Abstract][Full Text] [Related]
37. Study on the application of percutaneous closed pleural brushing combined with cell block technique in the diagnosis of malignant pleural effusion.
Wang K; Hu X; Chen Y; Yi X; Han X; Zhu D; Zhu B; Luo H
Clin Respir J; 2024 Jan; 18(1):e13705. PubMed ID: 37775991
[TBL] [Abstract][Full Text] [Related]
38. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.
Verma A; Chopra A; Lee YW; Bharwani LD; Asmat AB; Aneez DB; Akbar FA; Lim AY; Chotirmall SH; Abisheganaden J
Curr Drug Discov Technol; 2016; 13(2):68-76. PubMed ID: 27216707
[TBL] [Abstract][Full Text] [Related]
39. Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation.
Zou J; Bella AE; Chen Z; Han X; Su C; Lei Y; Luo H
J Int Med Res; 2014 Oct; 42(5):1110-7. PubMed ID: 25239875
[TBL] [Abstract][Full Text] [Related]
40. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
